As the U.S. market navigates a period of volatility with investors closely monitoring new tariffs and economic indicators, opportunities for growth can still be found in less conventional areas. Penny stocks, despite their somewhat outdated moniker, remain a relevant investment area for those interested in smaller or newer companies that might offer surprising value. By focusing on penny stocks with strong financial foundations, investors may discover potential long-term opportunities that larger firms often overlook.
Name | Share Price | Market Cap | Financial Health Rating |
Safe Bulkers (NYSE:SB) | $3.69 | $394.21M | ★★★★☆☆ |
Tuya (NYSE:TUYA) | $3.03 | $1.89B | ★★★★★★ |
Cango (NYSE:CANG) | $3.79 | $410.15M | ★★★★★★ |
Kiora Pharmaceuticals (NasdaqCM:KPRX) | $3.01 | $9.24M | ★★★★★★ |
Sensus Healthcare (NasdaqCM:SRTS) | $4.73 | $78.68M | ★★★★★★ |
TETRA Technologies (NYSE:TTI) | $3.36 | $477.94M | ★★★★☆☆ |
Imperial Petroleum (NasdaqCM:IMPP) | $2.45 | $75.22M | ★★★★★★ |
BAB (OTCPK:BABB) | $0.81 | $6.1M | ★★★★★★ |
QuantaSing Group (NasdaqGM:QSG) | $3.08 | $174.81M | ★★★★★★ |
CBAK Energy Technology (NasdaqCM:CBAT) | $0.7971 | $71.07M | ★★★★★☆ |
Click here to see the full list of 762 stocks from our US Penny Stocks screener.
We'll examine a selection from our screener results.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: 2seventy bio, Inc. is a cell and gene therapy company dedicated to researching, developing, and commercializing cancer treatments in the United States, with a market cap of $259.07 million.
Operations: The company generates revenue from its biotechnology segment, amounting to $37.86 million.
Market Cap: $259.07M
2seventy bio, Inc., a cell and gene therapy company, has recently agreed to be acquired by Bristol Myers Squibb for approximately US$286 million. Despite its current unprofitability and decreased revenue from US$100.39 million to US$37.86 million over the past year, the acquisition offers an 88% premium on its recent share price, signaling potential value recognition in its cancer treatment pipeline. The company's short-term assets of US$187.3 million exceed liabilities but do not cover long-term liabilities of US$228.6 million. With no debt and reduced losses over five years, it remains volatile with insider selling noted recently.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Equity Commonwealth (NYSE: EQC) is a Chicago-based, internally managed and self-advised real estate investment trust (REIT) focused on commercial office properties in the United States, with a market cap of approximately $173.19 million.
Operations: The company generates revenue primarily from the ownership and operation of office properties, totaling $57.57 million.
Market Cap: $173.19M
Equity Commonwealth, a Chicago-based REIT, reported US$47.98 million in revenue for the ten months ending October 2024, with net income of US$31.65 million despite a significant one-off loss of US$58.6 million impacting its results. The company is debt-free and has not diluted shareholders recently, while its seasoned management and board boast over a decade of experience on average. Although earnings have declined by 59.2% annually over five years and recent growth remains negative, EQC's short-term assets significantly exceed liabilities, providing financial stability amidst low return on equity and reduced profit margins year-over-year.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: DUKE Robotics Corp. is a robotics company operating in Israel and Europe with a market cap of $9.22 million.
Operations: The company generates revenue from its Industrial Automation & Controls segment, amounting to $0.11 million.
Market Cap: $9.22M
DUKE Robotics Corp., with a market cap of US$9.22 million, remains in the pre-revenue stage, generating only US$0.108 million in sales for 2024. Despite its unprofitability and high share price volatility, the company maintains sufficient cash runway exceeding one year and has improved its financial position by turning negative shareholder equity positive over five years. Recent strategic expansions include establishing Duke Robotics Greece to leverage opportunities within Greece's infrastructure sector, particularly through its IC Drone technology. The appointment of Alexandra Papaconstantinou as Managing Director underscores DUKE's commitment to strengthening international business relations and operational management in Europe.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGS:TSVT NYSE:EQC and OTCPK:DUKR.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.